Literature review highlights vasopressin's impact on speech function and mood in stroke patients, indicating potential therapeutic benefits.
The review of literature and own data on the role of vasopressin (AVP) in regulating of the functions of the CNS. In clinical investigations it has studied the central effects of selective agonist of V 2-receptor of AVP desmopressin (DDAVP) in the treatment of patients in the residual period after stroke. It was revealed: 1) positive influence of DDAVP on the speech function and attention in patients with various forms of aphasia, 2) reduction of anxiety and depression symptoms in patients with poststroke depression, and 3) improving the cerebral blood flow, especially in the area of the arteries, which developed stroke. The obtained data point to the new properties of vasopressin and enhance understanding of its functional role in humans giving new opportunities for its use in neurological patients.
No takes yet. Share an insight, caveat, or question.
Tsikunov et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: